Kinetics of protective antibodies are determined by the viral surface antigen

被引:73
作者
Pinschewer, DD
Perez, M
Jeetendra, E
Bächi, T
Horvath, E
Hengartner, H
Whitt, MA
de la Torre, JC
Zinkernagel, RM
机构
[1] Univ Zurich Hosp, Inst Expt Immunol, Dept Pathol, CH-8091 Zurich, Switzerland
[2] Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA
[4] Univ Zurich, Lab Electron Microscopy, Zurich, Switzerland
关键词
D O I
10.1172/JCI200422374
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Delayed and weak virus neutralizing antibody (nAb) responses represent a hallmark correlating not only with the establishment of persistent infection but also with unsuccessful vaccine development. Using a reverse genetic approach, we evaluated possible underlying mechanisms in 2 widely studied viral infection models. Swapping the glycoproteins (GPs) of lymphocytic choriomeningitis virus (LCMV, naturally persisting, noncytolytic, inefficient nAb inducer) and vesicular stomatitis virus (VSV, nonpersisting, cytolytic, potent nAb inducer) transferred the only target of nAb's from either virus to the other. We analyzed the nAb response to each of the 2 recombinant and parent viruses in infected mice and found that nAb kinetics were solely determined by the viral surface GP and not by the virus backbone. Moreover, the slowly and poorly nAb-triggering LCMV virion was a potent immunogenic matrix for the more antigenic VSV-GP. These findings indicate that the viral GP determines nAb kinetics largely independently of the specific viral infection context. They further suggest that structural features of viral GPs or coevolutionary adaptation of the virus's GP to the host's naive B cell repertoire, or both, may critically limit nAb kinetics and improvement of vaccine efficacy.
引用
收藏
页码:988 / 993
页数:6
相关论文
共 43 条
[31]   Specific cytoxic T cells eliminate cells producing neutralizing antibodies [J].
Planz, O ;
Seiler, P ;
Hengartner, H ;
Zinkernagel, RM .
NATURE, 1996, 382 (6593) :726-729
[32]   Rapid evolution of the neutralizing antibody response to HIV type 1 infection [J].
Richman, DD ;
Wrin, T ;
Little, SJ ;
Petropoulos, CJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :4144-4149
[33]   The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly [J].
Robison, CS ;
Whitt, MA .
JOURNAL OF VIROLOGY, 2000, 74 (05) :2239-2246
[34]  
Rose J.K., 2001, FIELDS VIROLOGY, P1221
[35]   An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants [J].
Rose, NF ;
Marx, PA ;
Luckay, A ;
Nixon, DF ;
Moretto, WJ ;
Donahoe, SM ;
Montefiori, D ;
Roberts, A ;
Buonocore, L ;
Rose, JK .
CELL, 2001, 106 (05) :539-549
[36]   Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1 [J].
Rose, NF ;
Roberts, A ;
Buonocore, L ;
Rose, JK .
JOURNAL OF VIROLOGY, 2000, 74 (23) :10903-10910
[37]  
SCOTT DW, 1970, CLIN EXP IMMUNOL, V6, P313
[38]   Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies:: Implications for passive and active immunization [J].
Seiler, P ;
Bründler, MA ;
Zimmermann, C ;
Weibel, D ;
Bruns, M ;
Hengartner, H ;
Zinkernagel, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :649-654
[39]   Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice [J].
Seiler, P ;
Kalinke, U ;
Rülicke, T ;
Bucher, EM ;
Böse, C ;
Zínkernagel, RM ;
Hengartner, H .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2253-2258
[40]   KILLING OF ANTIGEN-REACTIVE B-CELLS BY CLASS-II-RESTRICTED, SOLUBLE ANTIGEN-SPECIFIC CD8+ CYTOLYTIC LYMPHOCYTES-T [J].
SHINOHARA, N ;
WATANABE, M ;
SACHS, DH ;
HOZUMI, N .
NATURE, 1988, 336 (6198) :481-484